Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Sep 7:2021:2995602.
doi: 10.1155/2021/2995602. eCollection 2021.

Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI

Changqing Sun  1 , Wuyang Zheng  1 , Ling Liang  1 , Zuheng Liu  1 , Wenchao Sun  1 , Rong Tang  1
Affiliations
Randomized Controlled Trial

Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI

Changqing Sun et al. J Interv Cardiol. .

Abstract

Background: Little is known of the acute effects of ezetimibe in patients with acute coronary syndrome (ACS) undergoing PCI. We investigated whether ezetimibe improves inflammation and vascular endothelial function in patients with ACS undergoing PCI.

Methods: We randomized 171 patients with ACS undergoing PCI to receive ezetimibe 10 mg/day plus rosuvastatin 20 mg/day (combination group, n = 81) versus rosuvastatin 20 mg/day (rosuvastatin group, n = 90). Lipid profile, type II secretory phospholipase A2 (sPLA2-IIa), interleukin-1β (IL-1β), vascular cell adhesion molecule-1 (VCAM-1), and intercellular cell adhesion molecule-1 (ICAM-1) were measured at baseline and after 7 days. Three months after PCI, clinical outcomes were examined.

Result: The levels of sPLA2-IIa and IL-1β reduced significantly in both groups, but more when ezetimibe and rosuvastatin were coadministered (sPLA2-IIa: 6.16 ± 2.67 vs. 7.42 ± 3.53 ng/ml, p=0.01; IL-1β: 37.39 ± 26.25 vs. 48.98 ± 32.26 pg/ml, p=0.01). A significant rise of VCAM-1 and ICAM-1 was observed on day 7 after PCI in the both groups, but was less in the combination group (VCAM-1: 918.28 ± 235.31 vs. 988.54 ± 194.41 ng/ml, p=0.03; ICAM-1: 213.01 ± 100.15 vs. 246.88 ± 105.71 ng/ml, p=0.03). Patients in the combination versus rosuvastatin group appeared to suffer from less major adverse events. Periprocedural therapy of ezetimibe improves rosuvastatin effects on proinflammatory responses and endothelial function associated with ACS patients undergoing PCI. This trial is registered with https://clinicaltrials.gov/ct2/show/ChiCTR-IPR-17012219 (Chinese Clinical Trial Registry, http://www.chictr.org.cn on 02/08/2017).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Plasma levels of sPLA2-IIa, IL-1β, VCAM-1, and ICAM-1 in patients with ACS on baseline and 7th day after PCI.
See this image and copyright information in PMC

References

    1. Mortensen M. B., Afzal S., Nordestgaard B. G., Falk E. Primary prevention with statins. Journal of the American College of Cardiology. 2015;66(24):2699–2709. doi: 10.1016/j.jacc.2015.09.089. - DOI - PubMed
    1. Stone N. J. Statins in secondary prevention. Journal of the American College of Cardiology. 2017;69(22):2707–2709. doi: 10.1016/j.jacc.2017.04.018. - DOI - PubMed
    1. Nicholls S. J., Brandrup-Wognsen G., Palmer M., Barter P. J. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER) The American Journal of Cardiology. 2010;105(1):69–76. doi: 10.1016/j.amjcard.2009.08.651. - DOI - PubMed
    1. McCullough P. A. The antiinflammatory effects of statins. New England Journal of Medicine. 2001;345(16):1209–1211. doi: 10.1056/nejm200110183451613. - DOI - PubMed
    1. Lefer D. J. Statins as potent antiinflammatory drugs. Circulation. 2002;106(16):2041–2042. doi: 10.1161/01.cir.0000033635.42612.88. - DOI - PubMed

Publication types

MeSH terms

Substances